Clearance of Plasma EGFR Mutations as a Predictor of Outcome on Osimertinib in the AURA Trial

This poster presents an exploratory analysis into whether dynamic changes in the levels of plasma EGFR mutations post-osimertinib treatment are associated with clinical outcome. It presents data from the AURA Phase I study in patients with disease progression following prior therapy with an EGFR-TKI and T790M-positive baseline genotyping (in tumor tissue or plasma). It was found that early clearance of plasma EGFR mutations in patients receiving osimertinib therapy appears to be a prognostic marker for improved median progression-free survival of patients.